{"id":"chlorozotocin","rwe":[{"pmid":"39456132","year":"2021","title":"15th Report on Carcinogens.","finding":"","journal":"Report on carcinogens : carcinogen profiles","studyType":"Clinical Study"},{"pmid":"21860521","year":"2011","title":"Nitrosourea chemotherapeutic agents: Chlorozotocin.","finding":"","journal":"Report on carcinogens : carcinogen profiles","studyType":"Clinical Study"},{"pmid":"15320326","year":"2002","title":"Chlorozotocin.","finding":"","journal":"Report on carcinogens : carcinogen profiles","studyType":"Clinical Study"},{"pmid":"21089833","year":"2004","title":"Chlorozotocin.","finding":"","journal":"Report on carcinogens : carcinogen profiles","studyType":"Clinical Study"},{"pmid":"10557052","year":"1999","title":"Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming cells - implications for chemoprotective gene therapy.","finding":"","journal":"Leukemia","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Carcinogens","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["chlorozotocin","chlorozotocine"],"offLabel":[],"synonyms":["chlorozotocin","chlorozotocine"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells are like a factory, and DNA is the blueprint for making new parts. Chlorozotocin disrupts this blueprint, making it difficult for cancer cells to produce the parts they need to grow and multiply. This helps to slow down or stop the growth of cancer.","oneSentence":"Chlorozotocin works by interfering with DNA synthesis, which prevents cancer cells from growing and dividing.","technicalDetail":"Chlorozotocin is a nitrogen mustard alkylating agent that cross-links DNA, thereby inhibiting DNA replication and transcription, and ultimately leading to cell death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/612","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=chlorozotocin","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=chlorozotocin","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:35:23.881249","biosimilars":[],"competitors":[],"genericName":"chlorozotocin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05195723","phase":"PHASE1","title":"Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers","status":"COMPLETED","sponsor":"Moleculin Biotech, Inc.","startDate":"2022-05-11","conditions":["Healthy Volunteer"],"enrollment":48,"completionDate":"2022-10-24"},{"nctId":"NCT05365321","phase":"PHASE1,PHASE2","title":"Clinical Trial of Efficacy and Safety of Oral Drug in Adult Patients With COVID-19","status":"UNKNOWN","sponsor":"Andrei Carvalho Sposito","startDate":"2022-12","conditions":["COVID-19","Mechanical Ventilation Complication","COVID-19 Acute Respiratory Distress Syndrome"],"enrollment":75,"completionDate":"2023-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"3053LTY75Z","CHEBI":"CHEBI:82277","RXNORM":"1362886","UMLSCUI":"C0055465","ChEMBL_ID":"CHEMBL2094020","MESH_SUPPLEMENTAL_RECORD_UI":"C007028"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":182,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2021 Dec 21","pmid":"39456132","title":"15th Report on Carcinogens.","journal":"Report on carcinogens : carcinogen profiles"},{"date":"2011","pmid":"21860521","title":"Nitrosourea chemotherapeutic agents: Chlorozotocin.","journal":"Report on carcinogens : carcinogen profiles"},{"date":"2002","pmid":"15320326","title":"Chlorozotocin.","journal":"Report on carcinogens : carcinogen profiles"},{"date":"2004","pmid":"21089833","title":"Chlorozotocin.","journal":"Report on carcinogens : carcinogen profiles"},{"date":"1999 Nov","pmid":"10557052","title":"Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming cells - implications for chemoprotective gene therapy.","journal":"Leukemia"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"chlorozotocin","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Chlorozotocin is a small molecule originally developed by the National Cancer Institute. Its target and drug class are unknown, and it is not FDA-approved for any indications. As a result, there is limited information available on its commercial status, pharmacokinetics, or safety profile. Further research is needed to fully understand the properties and potential applications of chlorozotocin. Its development status and potential uses remain unclear.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}